Use of preclinical models for malignant pleural mesothelioma.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive cancer most commonly caused by prior exposure to asbestos. Median survival is 12-18 months, since surgery is ineffective and chemotherapy offers minimal benefit. Preclinical models that faithfully recapitulate the genomic and histopathological features of cancer are critical for the development of new treatments. The most commonly used models of MPM are two-dimensional cell lines established from primary tumours or pleural fluid. While these have provided some important insights into MPM biology, these cell models have significant limitations. In order to address some of these limitations, spheroids and microfluidic chips have more recently been used to investigate the role of the three-dimensional environment in MPM. Efforts have also been made to develop animal models of MPM, including asbestos-induced murine tumour models, MPM-prone genetically modified mice and patient-derived xenografts. Here, we discuss the available in vitro and in vivo models of MPM and highlight their strengths and limitations. We discuss how newer technologies, such as the tumour-derived organoids, might allow us to address the limitations of existing models and aid in the identification of effective treatments for this challenging-to-treat disease.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1468-3296
Volume Title
Publisher
Publisher DOI
Rights
Sponsorship
Medical Research Council (MR/R009120/1)
MRC (MR/V028669/1)
Engineering and Physical Sciences Research Council (EP/S009000/1)
National Institute for Health and Care Research (IS-BRC-1215-20014)